{"Clinical Trial ID": "NCT00373256", "Intervention": ["INTERVENTION 1:", "- Sunitinib + Paclitaxel", "After Cycle 1, an increase to 37.5 mg per day was allowed in the absence of complicated neutropenia and if all 3 doses of paclitaxel in Cycle 1 were successfully administered at 90 mg/m^2, at the discretion of the investigator. Paclitaxel could have been reduced to 65 mg/m^2 on the basis of tolerance; a further increase to 80 or 90 mg/m^2 was allowed upon recovery.", "INTERVENTION 2:", "Bevacizumab + Paclitaxel", "Paclitaxel could have been reduced to 65 mg/m^2 on the basis of tolerance; re-escalation to 80 or 90 mg/m^2 was allowed upon recovery."], "Eligibility": ["Incorporation criteria:", "\u2022 Advanced breast cancer diagnosis.", "A measurable disease according to RECIST (response assessment criteria) in solid tumours or bone diseases only.", "ECOG (Eastern Cooperative Oncology Group) Performance Status 0 or 1.", "- Exclusion criteria:", "No prior cytotoxic treatment in the advanced context of the disease.", "- HER2/neu positive unless trastuzumab has previously been received or is contraindicated.", "Treatment with a taxane in the adjuvant setting within a disease-free interval > 12 months after the end of treatment."], "Results": ["Performance measures:", "- Progression-free survival (PFS)", "Time between the date of randomization and the date of the first documentation on the progression or objective death of the tumour due to any cause, depending on the first of these causes. PFS = (first event date minus the date of randomization +1) divided by 30.4", "Time limit: From date of randomization to day 1 and every 8 weeks thereafter to 18 months or death", "Results 1:", "Title of arm/group: Sunitinib + Paclitaxel", "After cycle 1, an increase to 37.5 mg per day was allowed in the absence of complicated neutropenia and if all 3 cycle 1 paclitaxel doses were successfully administered at 90 mg/m^2, at the discretion of the investigator. Paclitaxel could have been reduced to 65 mg/m^2 on the basis of tolerance; a further increase to 80 or 90 mg/m^2 was allowed upon recovery.", "Total number of participants analysed: 242", "Median (95% confidence interval)", "Unit of measure: Month 7.4 (6.9 to 8.5)", "Results 2:", "Title of the arm/group: Bevacizumab + Paclitaxel", "- Arm/group description: Bevacizumab 10 mg/kg; duration of infusion according to standard of care. Initial Paclitaxel dose of 90 mg/m^2 as an hour infusion. Paclitaxel could have been reduced to 65 mg/m^2 based on tolerance; re-escalation to 80 or 90 mg/m^2 was allowed upon recovery.", "Total number of participants analysed: 243", "Median (95% confidence interval)", "Unit of measure: Month 9.2 (7.7 to 13.0)"], "Adverse Events": ["Undesirable Events 1:", "Total: 89/235 (37.87 per cent)", "Anemia 3/235 (1.28%)", "12/235 (5.11 per cent)", "- Leucopenia 1/235 (0.43%)", "Neutropenia 6/235 (2.55%)", "Pancytopenia 2/235 (0.85%)", "Thrombocytopenia 2/235 (0.85%)", "Atrial fibrillation 1/235 (0.43%)", "Congestive heart failure 1/235 (0.43%)", "Cardiogenic shock 1/235 (0.43%)", "Cardiovascular disorders 0/235 (0.00 %)", "Adverse Events 2:", "Total: 85/242 (35.12 per cent)", "Anemia 1/242 (0.41%)", "Febrile neutropenia 3/242 (1.24 %)", "- Leucopenia 0/242 (0.00 %)", "Neutropenia 2/242 (0.83%)", "Pancytopenia 0/242 (0.00 %)", "Thrombocytopenia 0/242 (0.00 %)", "Atrial fibrillation 2/242 (0.83%)", "Congestive heart failure 1/242 (0.41%)", "Cardiogenic shock 0/242 (0.00 %)", "Cardiovascular disorders 1/242 (0.41%)"]}